WO1995013091A1 - Methods of repairing connective tissues - Google Patents
Methods of repairing connective tissues Download PDFInfo
- Publication number
- WO1995013091A1 WO1995013091A1 PCT/US1994/013030 US9413030W WO9513091A1 WO 1995013091 A1 WO1995013091 A1 WO 1995013091A1 US 9413030 W US9413030 W US 9413030W WO 9513091 A1 WO9513091 A1 WO 9513091A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cartilage
- tissue
- matrix
- chondrocytes
- joint
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 89
- 210000002808 connective tissue Anatomy 0.000 title claims abstract description 26
- 210000000845 cartilage Anatomy 0.000 claims abstract description 85
- 108010067787 Proteoglycans Proteins 0.000 claims abstract description 62
- 102000016611 Proteoglycans Human genes 0.000 claims abstract description 62
- 210000001612 chondrocyte Anatomy 0.000 claims abstract description 56
- 210000001519 tissue Anatomy 0.000 claims abstract description 56
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 19
- 108010072582 Matrilin Proteins Proteins 0.000 claims abstract description 17
- 102000055008 Matrilin Proteins Human genes 0.000 claims abstract description 17
- 210000002435 tendon Anatomy 0.000 claims abstract description 16
- 208000014674 injury Diseases 0.000 claims abstract description 11
- 108091005804 Peptidases Proteins 0.000 claims abstract description 10
- 239000004365 Protease Substances 0.000 claims abstract description 10
- 238000002513 implantation Methods 0.000 claims abstract description 10
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 7
- 238000002278 reconstructive surgery Methods 0.000 claims abstract description 6
- 230000001684 chronic effect Effects 0.000 claims abstract description 5
- 238000002316 cosmetic surgery Methods 0.000 claims abstract description 5
- 230000001939 inductive effect Effects 0.000 claims abstract description 3
- 230000000694 effects Effects 0.000 claims description 31
- 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 claims description 28
- 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 claims description 28
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 claims description 27
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 claims description 27
- 239000011159 matrix material Substances 0.000 claims description 27
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 25
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 25
- 210000001188 articular cartilage Anatomy 0.000 claims description 25
- 210000002744 extracellular matrix Anatomy 0.000 claims description 25
- 210000003041 ligament Anatomy 0.000 claims description 23
- 229920001436 collagen Polymers 0.000 claims description 21
- 108010035532 Collagen Proteins 0.000 claims description 20
- 102000008186 Collagen Human genes 0.000 claims description 20
- 230000015572 biosynthetic process Effects 0.000 claims description 20
- 230000008439 repair process Effects 0.000 claims description 17
- 238000003786 synthesis reaction Methods 0.000 claims description 13
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 230000004044 response Effects 0.000 claims description 8
- 108010067219 Aggrecans Proteins 0.000 claims description 7
- 102000016284 Aggrecans Human genes 0.000 claims description 7
- 210000003035 hyaline cartilage Anatomy 0.000 claims description 7
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 230000003176 fibrotic effect Effects 0.000 claims description 5
- 210000003127 knee Anatomy 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 210000001179 synovial fluid Anatomy 0.000 claims description 5
- 208000012659 Joint disease Diseases 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000005499 meniscus Effects 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 102000016359 Fibronectins Human genes 0.000 claims description 3
- 210000003423 ankle Anatomy 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 230000008736 traumatic injury Effects 0.000 claims description 3
- 210000000707 wrist Anatomy 0.000 claims description 3
- 208000036487 Arthropathies Diseases 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims 3
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 claims 1
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 56
- 238000011282 treatment Methods 0.000 abstract description 37
- 230000007850 degeneration Effects 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 238000004519 manufacturing process Methods 0.000 abstract description 13
- 208000035475 disorder Diseases 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 5
- 230000008733 trauma Effects 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- 239000004033 plastic Substances 0.000 abstract description 3
- 229920003023 plastic Polymers 0.000 abstract description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 17
- 210000000988 bone and bone Anatomy 0.000 description 16
- 239000007943 implant Substances 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000001356 surgical procedure Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 8
- 229940059329 chondroitin sulfate Drugs 0.000 description 8
- 229920000288 Keratan sulfate Polymers 0.000 description 7
- 230000003412 degenerative effect Effects 0.000 description 7
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000007634 remodeling Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 101710132601 Capsid protein Proteins 0.000 description 5
- 108010003272 Hyaluronate lyase Proteins 0.000 description 5
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 5
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 5
- 150000002016 disaccharides Chemical group 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 210000002832 shoulder Anatomy 0.000 description 4
- 208000008884 Aneurysmal Bone Cysts Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 229920002567 Chondroitin Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000004931 aggregating effect Effects 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 230000022159 cartilage development Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 210000000968 fibrocartilage Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000008407 joint function Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002346 musculoskeletal system Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 210000004061 pubic symphysis Anatomy 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 210000001562 sternum Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000004317 Lyases Human genes 0.000 description 2
- 108090000856 Lyases Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000906034 Orthops Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- 210000001608 connective tissue cell Anatomy 0.000 description 2
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 210000001513 elbow Anatomy 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000003328 fibroblastic effect Effects 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 2
- 210000000281 joint capsule Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000005226 mechanical processes and functions Effects 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 210000001738 temporomandibular joint Anatomy 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 1
- 108010055851 Acetylglucosaminidase Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000018963 Chondroitin Lyases Human genes 0.000 description 1
- 108010026719 Chondroitin Lyases Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical group OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000581652 Hagenia abyssinica Species 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 102100039285 Hyaluronidase-2 Human genes 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 description 1
- 101710156134 Hyaluronoglucuronidase Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Chemical group CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Chemical group CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 102100031688 N-acetylgalactosamine-6-sulfatase Human genes 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Chemical group CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100030122 Protein O-GlcNAcase Human genes 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010041738 Sports injury Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- -1 but not exclusively Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000007978 cacodylate buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008421 cartilage matrix synthesis Effects 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000005548 dental material Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003733 fiber-reinforced composite Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000001981 hip bone Anatomy 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 210000003559 hypertrophic chondrocyte Anatomy 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 108010011519 keratan-sulfate endo-1,4-beta-galactosidase Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108700041430 link Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000000426 patellar ligament Anatomy 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108010054626 proteoglycan-degrading metalloendopeptidases Proteins 0.000 description 1
- 238000011470 radical surgery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000009645 skeletal growth Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/08—Muscles; Tendons; Ligaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/38—Joints for elbows or knees
- A61F2/3872—Meniscus for implantation between the natural bone surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3645—Connective tissue
- A61L27/3654—Cartilage, e.g. meniscus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3645—Connective tissue
- A61L27/3662—Ligaments, tendons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3852—Cartilage, e.g. meniscus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/386—Ligaments, tendons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
- C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- musculoskeletal system is not only an efficient system for delivering useful mechanical energy and load support, but is also capable of synthesizing, processing and organizing complex macromolecules to fashion tissues and organs for specific mechanical functions.
- An important subset of organs of the musculoskeletal system are the joints. Many types of joints exist in the body. Freely moving joints (ankle, elbow, hip, knee, shoulder, and those of the fingers, toes and wrist) are known as diarthrodial or synovial joints.
- the intervertebral joints of the spine are not diarthrodial joints as they are fibrous and do not move freely. They do, however, provide the flexibility required by the spine.
- Diarthrodial joints enable local motion and other activities of daily life to take place. They perform their function so well that we are often not even aware of their existence nor the function they provide until injury strikes or arthritis develops. From an engineering point of view, these natural bearings are very uncommon structures. Under healthy conditions, they function nearly frictionless and remain almost entirely wear-resistant manner throughout our lives. Failure of the bearings surfaces of the body (i.e. articular cartilage), as with engineering bearings, means a failure of these bearings to provide their central functions. In biomedical terms, failure of diarthrodial joints leads to arthritis. The most common form being Osteoarthrisis or Osetoarthrothesis. Repair of arthritic joints means orthopedic surgery to replace the worn-out joints by a prosthesis or by a biological graft. This is an enormous medical and economic problem, with more than thirty million Americans suffering from the disabling disease.
- Diarthrodial joints have some common structural features. First, all diarthrodial joints are enclosed in a strong fibrous capsule. Second, the inner surfaces of the joint capsule are lined with a metabolically active tissue, the synovium, which secretes the synovial fluid that lubricates the joint and provides the nutrients required by the avascular cartilage. Third, the articulating bone ends in the joint are lined with a thin layer of hydrated soft tissue known as articular cartilage. These linings, i.e. the synovium and articular cartilage layers, form the joint cavity which contains the synovial fluid. Thus, in animal joints, the synovial fluid, articular cartilage, and the supporting bone form the bearing system which provides the smooth nearly- frictionless bearing system of the body.
- Hyaline cartilage as the names implies is glass smooth, glistening and bluish white in appearance, although older or diseased tissue tends to lose this appearance.
- Articular cartilage is characterized by a particular structural organization. It consists of specialized cells (chondrocytes) embedded in an intercellular material (typically referred to as "cartilage matrix”) which is rich in proteoglycans, collagen fibrils, other proteins, and water. Cartilage tissue is neither innervated nor penetrated by the vascular or lymphatic systems.
- the underlying subchondral bone tissue - which forms a narrow, continuous plate between the bone tissue and the cartilage- is innervated and vascularized. Beneath this bone plate, the bone tissue forms trabeculae, containing the marrow.
- articular cartilage is underlined by only primary bone trabeculae.
- a portion of the meniscal tissue in joints (referred to as the "interarticular” cartilage) also consists of cartilage whose make-up is similar to articular cartilage. It is generally believed that because articular cartilage lacks a vasculature, damaged cartilage tissue does not received sufficient or proper stimuli to elicit a repair response.
- the menisci of the knee, and other similar structures such as the disc of the temporomandibular joint and the labrum of the shoulder, are specialized fibrocartilagenous structures which perform functions which are vital for normal joint function. They are known to assist the articular cartilage in distributing loads across the joint, assist the ligaments and tendons in providing joint stability, play a major role in shock absorption, and may assist in lubrication of the joint. Damage to these structures can lead to a reduction in joint function and degeneration of the articular cartilage. Surgical removal can result in early onset of osteoarthritis.
- the menisci, disc and labrum are hydrated fibrocartilage structures composed primarily of collagen (type I) with smaller amounts of other collagens and proteoglycans (including aggrecan and the smaller, non-aggregating proteoglycans). They contain a sparse population of cells which, like the chondrocytes of cartilage, are responsible for the synthesis and maintenance of this extracellular matrix.
- Skeletal ligaments are specialized connective tissues that connect bones.
- Ligaments are composed primarily of type I collagen organized in parallel arrays, with small amounts of other collagens, proteoglycans, elastin and other proteins and glycoproteins.
- the cells are fibroblastic in the midsubstance, and appear more chondroid at and near the insertion sites.
- Tendons have a similar structure, with a relatively high concentration of collagen, organized primarily as fibers in parallel.
- Other components are proteoglycans, elastin and other proteins and glycoproteins.
- the cells are fibroblastic in nature. The cells of the tendon and ligament are metabolically active and are responsible for the synthesis and maintenance of this extracellular matrix.
- Proteoglycans comprise the second largest portion of the organic material in articular cartilage. These macromolecules are composed of a protein core to which are attached a number of covalently bound GAG chains (chondroitin sulfate and keratan sulfate). There are many different types of proteoglycans present in a wide range of tissues throughout the body; presumably, they also have different functions in the various tissues. However, the most extensively studied proteoglycans have been those from articular cartilage because of its role in regulating skeletal growth, joint function and the development of arthritis.
- the major proteoglycans present in articular cartilage are the large aggregating type (50-85%) and the large non-aggregating type (10-40%) with distinct small proteoglycans also present.
- the molecular weights of these proteoglycan monomers range from 1 x 10 ⁇ to 4 x 10 ⁇ , and they contribute significantly to the mechanical and physicochemical properties of cartilage. These molecules are highly ordered structures with length scales ranging from 10 ⁇ 8 to 10 ⁇ 6 m.
- an extended protein core with several distinct regions: an N-terminal region with two globular domains (Gl and G2), a keratan sulfate-rich domain, a longer chondroitin sulfate-rich domain which may also contain some interspersed keratan sulfate and neutral oligosaccharide chains, and a C-terminal globular domain (G3) on the proteoglycan monomer.
- G3 C-terminal globular domain
- proteoglycan-hyaluronan bond is stabilized by a separate globular link protein (mw, 41,000-48,000), and this stabilization is vital in providing additional strength to the molecular network formed by proteoglycans in concentrated solutions.
- the structure of proteoglycan in cartilage is not uniform.
- the size of the proteoglycan aggregate depends mainly on the size of the hyaluronate chain and may be as large as 350 x 10 ⁇ , particularly in fetal cartilage. Differences in chain length and amounts of keratan sulfate and chondroitin sulfate, length of the protein core, and degree of aggregation all contribute to the compositional and structural heterogeneties of proteoglycans within the tissue.
- chondroitin sulfate (CS: ⁇ mw, 20,000) is composed of repeating disaccharide units of glucuronic acid and N- acetylgalactosamine with a sulfate (SO4) group and a carboxyl (COOH) group per disaccharide.
- SO4 sulfate
- COOH carboxyl
- Keratan sulfate (KS) consists of repeating disaccharide units of galactose and N-acetylglucosamine, again averaging approximately one SO4 group per disaccharide. Keratan sulfate content of proteoglycans increases with age from zero in fetal cartilage to a maximum in aging cartilage. Both proteoglycan content and size decrease with increasing " severity of OA.
- the physical interactions between collagen and proteoglycan can arise from two sources: electrostatic and mechanical.
- Surgical procedures account for only a fraction of the treatment of individuals who suffer from disabling diseases resulting from connective tissue damage and degeneration in synovial joint.
- Alternative treatment includes conservative treatment (e.g., rest and physical therapy), and treatment is largely directed at symptomatic relief through the use of analgesics and nonsteroidal anti- inflammatory drugs.
- Figure 1 illustrates the dose-dependent synthesis of aggrecan by chondrocytes treated with chondroitin ABC lyase.
- the binding of an anti-aggrecan antibody (PG-Lt) was measured immediately after chondroitinase treatment ("0 days") and 4 days subsequent. As described below, antibody binding was assessed by EIA techniques utilizing detection of substrate release (absorbance at 405nm).
- the present invention relates to the use of an ECM-altering enzymatic activity, such as a proteoglycanase or a protease, to stimulate the generation of cartilage tissue by inducing chondrocytes to synthesize new cartilage matrix.
- an ECM-altering enzymatic activity such as a proteoglycanase or a protease
- treating chondrocytes with an enzymatic activity that modifies the territorial ECM of the cell, especially cell surface proteoglycans can in and of itself be sufficient to stimulate cartilage production by the chondrocytes.
- the subject invention can be employed therapeutically to correct or prevent degeneration of connective tissue.
- the present method can be used in the treatment of disorders comprising cartilage such as found in an diarthroidal joint (e.g.
- articular and interarticular cartilage as well as in the treatment of tendon and ligamental tissues.
- Such disorders can range from chronic degeneration brought about by disease, overuse, or trauma, to plastic or reconstructive surgery.
- the subject method may also be applied to both the development and implantation of prosthetic devices.
- Cartilage, ligament, tendon, menisci, disc of tempromanibular joint and labrum of the shoulder are metabolically active connective tissue. They consist of an extracellular matrix (ECM) that contains a population of cells (chondrocytes in hyaline cartilage and the like, and fibrochondrocytes in fibrocartilage, such as meniscal cartilage), wherein the synthesis and maintenance of the tissue are dependent on the appropriate activities of the chondrocytes (or fibrochondrocytes, or other connective tissue cell) associated with it.
- ECM extracellular matrix
- the metabolic activities involve both anabolic and catabolic events, which include: (a) the synthesis of matrix components, (b) the incorporation and organization of these components into the matrix, and (c) their degradation and loss from the matrix.
- the chondrocytes are responsible for orchestration of these events, and their appropriate balance results in a maintenance of the cartilage matrix and its biological function. These cells have the capacity to respond to their environment.
- the effector agents may be soluble mediators (such as growth factors, cytokines, pharmaceutical agents), matrix composition, hydrostatic pressure, and mechanical load. In normal conditions, these responses are designed to maintain a functional matrix. However, some stimulators may result in the cells responding in a manner which degrades the ECM, or in a manner which results in failed repair, and degradation of the ECM occurs.
- the present invention relates to the use of an enzymatic activity, such as a chondroitinase, keratanase, hyaluronidase or protease activity, to stimulate production of a connective tissue matrix by the cells within that matrix.
- an enzymatic activity such as a chondroitinase, keratanase, hyaluronidase or protease activity
- protease activity we refer specifically to those proteases that do not substantially cleave the collagen matrix. Rather, protease activity refers specifically to those proteases that act only on the proteins of the proteoglycan element of the matrix, and the like.
- the present invention arises from the unexpected finding that enzymatically altering the extracellular matrix of a connective tissue cell, particularly of a chondrocyte, has a stimulatory effect on the production of cartilage matrix and other connective tissue matrices by the treated cells.
- the subject method is applicable in vivo, as for example, in the restoration or remodeling of a connective tissue. This procedure has the potential to slow, stop, or reverse the progression of the degeneration of connective tissue, such as occurs in osteoarthritis, rheumatoid arthritis and other chronic joint disorders.
- the present method can be used to treat connective tissue which has undergone traumatic injury or excessive wear, or which is the subject of reconstructive/plastic surgery.
- the subject method is particularly suitable for application in treatments wherein the cartilage generated is to remain unossified.
- the use of the subject method in healing processes can provide correct regeneration of the connective tissue and thereby reduce the amount of fibrotic tissue that might otherwise occur.
- Another aspect of the present method involves the use of such ECM- altering enzymatic activities to stimulate production of cartilage in vitro, such as in the generation of prosthetic devices.
- a great deal of effort has been exerted over the years to facilitated regeneration and repair of bone and cartilage.
- Several techniques, including cartilage implants and bone implants and grafts for the remedy of many skeletal disorders and chondrodystropies, can be enhanced by use of the present methods and formulations, both during the formation of the prosthetic and after implantation.
- chondrocytes with an enzymatic activity that modifies the territorial ECM of the cell, especially cell surface proteoglycans, can in and of itself be sufficient to stimulate cartilage production by the chondrocytes.
- the present therapeutic methods have a number of advantages over prior techniques used to repair cartilage.
- an enzymatic activity such as a chondroitinase
- a tighter regulation of the types of cells stimulated during treatment can be achieved.
- mitogenic agents such as growth factors or cytokines which can elicit responses in a broad range of cells, including cells whose activities can be detrimental to cartilage repair.
- many mitogens have the effect of stimulating osteogenesis in addition to chondro genesis, and therefore result in induction of bone formation.
- the ECM-altering activity useful in the present invention is an enzyme or other catalytic activity which sufficiently alters the extracellular matrix of a chondrocyte, especially the proteoglycans of the territorial matrix of the cell, so as to induce the chondrocytes to synthesize cartilage matrix.
- the ECM- altering activity is a proteoglycanase which digests chondroitin sulfate glycosaminoglycan chains of proteoglycans associated with the chondrocytes.
- Such enzymatic activities can also digest other GAG chains, including dermatan sulfate and hyaluronate.
- the proteoglycanase is a dissacharidase, such as a chondroitin lyase (chondroitinase), which can catalyze the depolymerization of chondroitin sulfate GAGs, particularly chondroitin-6-sulfate and chondroitin-4- sulfate, by the elimination of 1,4 hexosaminidic bonds.
- chondroitinase chondroitin lyase
- chondroitin ABC lyase (EC 4.2.2.4) is a particularly useful chondroitinase activity which catalyzes depolymerization of a glycosaminoglycan containing 1,4-b-D-hexosaminyl and 1,3-b- D-glucuronosyl or 1,3-a-D-iduronosyl linkages by elimination of D-4,5-D-glucuronate residues from the glycosaminoglycan.
- proteoglycanase activities useful in the present invention include chondroitin AC lyase (EC 4.2.2.5), Hyaluronoglucosaminidase (EC 3.2.1.35), Hyaluronoglucuronidase (EC 3.2.1.36), ⁇ - N-acetylglucosaminidase (EC 3.2.2.30), Hyaluronate lyase (EC 4.2.2.1),
- the present invention further contemplates the use of other hydrolases or lyases, including engineered enzymes and catalytic antibodies, which alter the extracellular matrix of the chondrocytes so as to stimulate these cell to initiate cartilage matrix synthesis.
- hydrolases or lyases including engineered enzymes and catalytic antibodies, which alter the extracellular matrix of the chondrocytes so as to stimulate these cell to initiate cartilage matrix synthesis.
- One class of enzymes of use in the subject method are proteases which act to cleave the core protein of chondrocyte-bound proteoglycans.
- the chondrocytes are contacted with a trypsin-like activity able to release cell surface proteoglycans by cleaving the core protein of a proteoglycan, such as aggrecan.
- the ECM-altering activity acts primarily on the proteoglycan matrix and leaves any collagen matrix surrounding the chondrocyte substantially intact.
- substantially intact it is meant that no more than 20% of the collagen matrix in the treatment area is enzymatically altered, and more preferably, no more than 5% is altered, and most preferably, no more than 2%. It can be especially advantageous to avoid use of enzymes which, particularly at high concentration, decrease the tensile strength of the collagen matrix in the treatment area.
- the ECM-altering agent can be generated as a chimeric protein comprising an additional moiety that binds a component of the extracellular matrix.
- a chimeric molecule can be useful in circumstances wherein diffusion of the enzyme from a treatment site is undesirable, and will function to such an end by virtue of localizing the chimeric molecule at or proximate a treatment site.
- a ECM- altering enzyme of this embodiment can be generated as the product of a fusion gene, or by chemical cross-linking.
- ECM extracellular matrix
- a chimeric ECM-altering agent such as a chondroitinase-containing chimeric protein
- fibronectin a well characterized protein
- Fibronectin is a large adhesive glycoprotein with multiple functional domains. Several of these domains have matrix attachment activity. For example, one of these is a single "type-Ill repeat" which contains a tetrapeptide sequence R-G-D-S (Pierschbacher et al. (1984) Nature 309:30-3; and Kornblihtt et al. (1985) EMBO 4:1755-9).
- an RGDS sequence is added to chondroitin ABC lyase to produce a chondroitinase activity having additional ECM localizing characteristics.
- the ECM-altering enzyme, or pharmaceutically acceptable salts thereof may be conveniently formulated for administration with a biologically acceptable medium, such as water, buffered saline, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like) or suitable mixtures thereof.
- a biologically acceptable medium such as water, buffered saline, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like) or suitable mixtures thereof.
- a biologically acceptable medium includes any and all solvents, dispersion media, and the like which may be appropriate for the desired route of administration of the pharmaceutical preparation. The use of such media for pharmaceutically active substances is known in the art.
- the pharmaceutical formulation includes, although not exclusively, solutions or a freeze-dried powder of at least one ECM- altering enzyme in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered media at a suitable pH and isosmotic with physiological fluids.
- composition of formulations which may be prepared in the form of solutions for the treatment of connective tissues with an ECM-altering activity are given in the della Valle U.S. Patent No. 5,218,094.
- supporting excipients such as, but not exclusively, mannitol or glycine may be used and appropriate buffered solutions of the desired volume will be provided so as to obtain adequate isotonic buffered solutions of the desired pH.
- Similar solutions may also be used for the pharmaceutical compositions of the enzyme in isotonic solutions of the desired volume and include, but not exclusively, the use of buffered saline solutions with phosphate or citrate at suitable concentrations so as to obtain at all times isotonic pharmaceutical preparations of the desired pH, for example, neutral pH.
- Methods of introducing the ECM-altering activity at the site of treatment include, but are not limited to, intra-articular, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, oral, topical, and intranasal. Methods of introduction may also be provided by rechargable or biodegradable devices.
- Various slow release polymeric devices have been developed and tested in vivo in recent years for the controlled delivery of drugs, including proteinacious biopharmaceuticals.
- a variety of biocompatible polymers including hydrogels, including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of the enzymatic agent at a particular target site.
- An essential feature of certain embodiments of the implant can be the linear release of the ECM-altering enzyme, which can be achieved through the manipulation of the polymer composition and form.
- the amount of water, porosity and consequent permeability characteristics can be controlled.
- the selection of the shape, size, polymer, and method for implantation can be determined on an individual basis according to the disorder to be treated and the individual patient response. The generation of such implants is generally known in the art. See, for example, Concise Encyclopedia of Medical & Dental Materials, ed. by David Williams (MIT Press: Cambridge, MA, 1990); and the Sabel et al. U.S. Patent No. 4,883,666.
- a source of cells producing the ECM-altering agent, or a solution of hydrogel matrix containing a purified ECM-altering enzyme is encapsulated in implantable hollow fibers.
- Such fibers can be pre-spun and subsequently loaded with both agents (Aebischer et al. U.S. Patent No. 4,892,538; Aebischer et al. U.S. Patent No. 5,106,627; Hoffman et al. (1990) Expt. Neurobiol. 110:39-44; Jaeger et al. (1990) Prog. Brain Res. 82:41-46; and Aebischer et al. (1991) J. Biomech. Eng.
- the ECM-altering enzyme is a chondroitin ABC lyase
- the therapeutically effective amount of the enzyme will typically be in the range of .005- 200 Units/ml, and, more preferably, in the range of .1-20 Units/ml.
- Unit is defined as the quantity of chondroitinase that catalyzes the formation of 1 mmole of unsaturated disaccharide from chondroitin-6-sulfate per min. at 37°C, pH 8.0.
- the present invention makes available effective therapeutic methods and compositions for restoring cartilage function to a connective tissue.
- Such methods are useful in, for example, the repair of defects or lesions in cartilage tissue which is the result of degenerative wear such as that which results in arthritis, as well as other mechanical derangements which may be caused by trauma to the tissue, such as a displacement of torn meniscus tissue, meniscectomy, a laxation of a joint by a torn ligament, malignment of joints, bone fracture, or by hereditary disease.
- the present reparative method is also useful for remodeling cartilage matrix, such as in plastic or reconstructive surgery, as well as periodontal surgery.
- the present method may also be applied to improving a previous reparative procedure, for example, following surgical repair of a meniscus, ligament, or cartilage. It may prevent the onset or exacerbation of degenerative disease if applied early enough after trauma.
- the subject method is used therapeutically to generate a cartilage repair response in a connective tissue by stimulating chondrocytes (or fibrochondrocytes) embedded in the tissue to synthesize cartilage matrix.
- connective tissues as articular cartilage, interarticular cartilage (menisci), costal cartilage (connecting the true ribs and the sternum), ligaments, and tendons are particularly amenable to treatment in reconstructive and/or regenerative therapies using the subject method.
- regenerative therapies include treatment of degenerative states which have progressed to the point of which impairment of the tissue is obviously manifest, as well as preventive treatments of tissue where degeneration is in its earliest stages or imminent.
- the subject method can further be used to prevent the spread of mineralisation into fibrous tissue.
- the subject method is used to treat cartilage of a diarthroidal joint, such as knee, an ankle, an elbow, a hip, a wrist, a knuckle of either a finger or toe, or a temperomandibular joint.
- the treatment can be directed to the meniscus of the joint, to the articular cartilage of the joint, or both.
- the subject method can be used to treat a degenerative disorder of a knee, such as which might be the result of traumatic injury (e.g., a sports injury or excessive wear) or osteoarthritis.
- An injection of an ECM-altering agent into the joint with, for instance, an arthroscopic needle can be used to treat the afflicted cartilage.
- the injected agent can be in the form of a hydro gel or other slow release vehicle described above in order to permit a more extended and regular contact of the agent with the treated tissue.
- the ECM-altering enzyme can be formulated and delivered to a specific location.
- slow release polymers can be localized to a particular treatment area of a mensical disc.
- degenerative changes are prominent in the triangular cartilage disc of the wrist joint of elderly people. The degeneration is more frequent and advanced on the ulnar side of the disc, perhaps because the biomechanical forces are more intense on that side. The degeneration affects the avascular portions of the disc but not the vascularized edges.
- an ECM-altering enzyme can be localized to the center of the ulnar face of the disc to enhance reparative process in that portion of the disc without substantially altering the integrity of the rest of the disc.
- the subject method can be used to treat cartilage of the costal sternum. After open chest surgery, such treatment can be opportunely employed in speeding reattachment of severed ribs to the sternum, as well as to decrease the amount of fibrotic tissue generated during healing.
- an ECM-altering agent is contacted with cartilage of the pubic symphysis to enhance reattachment of the hip bones.
- such treatments can be utilized in a female patient after delivery of a baby in order to mediate healing of the pubic symphysis which has undergone an intracartilaginous fissure from the degeneration of hyaline cartilage before and during labor.
- the subject method is applied to prevent replacement of hyaline cartilage after injury or other degenerative disorders, by other kinds of connective tissue such as fibroses or fibrous cartilage, as well as to prevent ossification of cartilaginous tissues.
- the present invention can be used in the treatment of disorders in which cartilage is replaced by bone
- Treatment of this tissue by the subject method can inhibit the spread of mineralisation into the cartilage tissue by stimulating production of new cartilage matrix which turns over or otherwise replaces cartilage which is undergoing osteogenic processes.
- the present invention further contemplates the use of the subject method in the field of cartilage transplantation and prosthetic device therapies.
- the growth of new cartilage from either transplantation of autologous or allogenic cartilage has been largely unsuccessful.
- the zonal arrangement of these tissues may reflect a gradual change in mechanical properties, and failure occurs when implanted tissue, which has not differentiated under those conditions, because the implant lacks of the ability to appropriately respond. For instance, when meniscal cartilage is used to repair anterior cruciate ligaments, the tissue undergoes a metaplasia to pure fibrous tissue.
- the present invention can be used to particularly addresses this problem, by causing the implanted cells to become more adaptive to the new environment and effectively resemble hypertrophic chondrocytes of an earlier developmental stage of the tissue.
- the action of chondrogensis in the implanted tissue, as provided by the subject method, and the mechanical forces on the actively remodeling tissue will synergize to produce an improved implant more suitable for the new function to which it is to be put.
- the subject method can be applied to enhance remodeling of ligaments or tendons that are surgically shortened.
- the present invention can be used to treat temperomandibular joint dysfunction (TMJ) either in regenerating the disc (as described for other joints above) or in the repair or replacement of the ligamental tissue which articulates the disc with the surrounding skeletal bones to correctly position the disc on the head of the condyle.
- TMJ temperomandibular joint dysfunction
- the ligaments have been stretched such that the interarticular disc is positioned either anterior or posterior to the condyle head. Surgical procedures to shorten the ligaments have been used to correct this deformity.
- the subject method can be used in the treatment of the shortened ligament to provide an improved ligament having zonal patterning that has advantageously been developed by the active remodeling of the "new" ligament by chondrocyte activation. Moreover, the present invention can prevent the occurrence of fibrotic tissue in the shortened ligament.
- the subject method can be applied to enhancing both the generation of prosthetic cartilage devices and to their implantation.
- the need for improved treatment has motivated research aimed at creating new cartilage that is based on collagen-glycosaminoglycan templates (Stone et al. (1990) Clin Orthop Relat Red 252:129), isolated chondrocytes (Grande et al. (1989) J Orthop Res 7:208; and Takigawa et al. (1987) Bone Miner 2:449), and chondrocytes attached to natural or synthetic polymers (Walitani et al. (1989) J Bone Jt Surg 71B:74; Vacanti et al.
- chondrocytes can be grown in culture on biodegradable, biocompatible highly porous scaffolds formed from polymers such as polyglycolic acid, polylactic acid, agarose gel, or other polymers which degrade over time as function of hydrolysis of the polymer backbone into innocuous monomers.
- the matrices are designed to allow adequate nutrient and gas exchange to the cells until engraftment occurs.
- the cells can be cultured in vitro until adequate cell volume and density has developed for the cells to be implanted.
- One advantage of the matrices is that they can be cast or molded into a desired shape on an individual basis, so that the final product closely resembles the patient's own ear or nose (by way of example), or flexible matrices can be used which allow for manipulation at the time of implantation, as in a joint.
- the implants are contacted with an ECM-altering activity during the culturing process, such as a chondroitinase, in order to further stimulate cartilage matrix production within the implant.
- an ECM-altering activity such as a chondroitinase
- the cultured cells continue to maintain a phenotype typical of a chondrogenic cell (i.e. hypertrophic), rather than mature chondrocytes, and hence continue the population of the matrix and production of cartilage tissue.
- the implanted device is treated with an ECM- altering activity in order to actively remodel the implanted matrix so as to make it more suitable for its intended function.
- the artificial transplants suffer from the same deficiency of not being derived in a setting which is comparable to the actual mechanical environment in which the matrix is implanted.
- the activation of the chondrocytes in the matrix by the subject method can allow the implant to acquire characteristics similar to the tissue for which it is intended to replace.
- the present invention is used to enhance attachment of prosthetic devices.
- the subject method can be used in the implantation of a periodontal prosthesis, wherein the treatment of the surrounding connective tissue stimulates formation of periodontal ligament about the prosthesis, as well as inhibits formation of fibrotic tissue proximate the prosthetic device.
- This experiment was designed to determine the cytotoxicity of chondroitinase for bovine articular cartilage cells in sub-confluent primary culture. These cells were pre- incubated for 48 hours in standard wells in Ham's F-12 medium with and without 10% fetal bovine serum. The medium was removed and replaced with the same medium containing no chondroitinase ABC (control) or from 0.5-00005 units/ml. of chondroitinase ABC. The cells were incubated for 48 hours, fixed, and counted. The results of this experiment are presented in Table One.
- the primary difference between the two parallel experiments was the age of the culture before exposure to chondroitinase,
- the cells represented a primary culture while in the other the cells were put through 5 passages.
- a certain percentage of the chondroblasts revert to a fibroblast-like phenotype. That is, while still retaining some cartilage ECM capacity, they also behave like fibroblast.
- these cells begin synthesizing large quantities of chondroitin-6-sulfate containing proteoglycans.
- Chondroitinase ABC was a derivative of the bacterium Proteus vulgaris obtained from one of two sources, Seikagaku America and Taiyo Fishery Co., Ltd.
- Anti proteoglycan specific for one of chondroitin-6-sulfate or chondroitin-4-sulfate were obtained from ICN.
- These mouse monoclonal antibodies are able to recognize epitopes of the core protein of cartilage proteoglycan normally containing one of either chondroitin-6-sulfate or 4-sulfate, respectively.
- Anti-mouse IgG goat-biotin was also purchased from ICN.
- Streptavidin-Alkaline phosphatase was purchased fro GIBCO.
- p-Nitrophenylphosphate was used as the substrate for the enzyme reaction.
- the washing and sample buffer was a mixture of PBS and 0.05% Tween 20.
- Chondrocytes from bovine articular cartilage were removed from the extracellular matrix (ECM) by dissolving the ECM with collagenase. The were placed in Ham's medium containing fetal bovine serum (see Example 1) and cultured in 100mm petri dishes for either three weeks, with three passages into fresh medium (set #1) or for five weeks and five passages (set #2).
- the first antibody (e.g. directed to the proteoglycan) was added to the plates and incubated for eighteen hours at 4° C. After incubation, the wells were washed with rinsing buffer three times before the addition of the second antibody.
- the second antibody (Goat anti-mouse IgG-biotin conjugate) was added to the wells, and the cells were incubated for two hours at room temperature. The wells were then washed with rinsing buffer three times before the addition of the phosphatase- streptavidin conjugate, and incubated for two hours. The plates were then washed three times with rinsing buffer before enhancement.
- the plates were treated with 0.1% para-nitrophenylphosphate in buffer containing 22 mmol/1 sodium carbonate, 28 mmol/1 sodium bicarbonate, and 1 mmol/1 magnesium chloride (pH 9.8) for 30 minutes. After enhancement the optical density at 405 nm was measured for each of the wells.
- Ch-6-S Mean 0.648 0.564 0.640 0.631 0.658
- Ch-4-S Mean 0.248 0.247 0.268 0.297 0.327
- Table 2 illustrates the results of the chondroitinase treatment of the set #1 cells.
- the data indicates that the production of proteoglycan comprising chondroitin-4-sulfate increases with increasing concentration of chondroitinase ABC. Conversely, the proteoglycan comprising chondroitin-6-sulfate was not significantly altered with chondroitin ABC treatment. This experiment demonstrates that chondrocytes are stimulated to produce new cartilage proteoglycan.
- Table 3 illustrates the results of the experiment with the older chondrocyte primary culture (set #2). Additionally, there is a small increase in the amount of chondroitin-6-sulfate with increased doses of chondroitinase, presumably resulting from the activity of chondrocytes that have reverted to fibroblasts. There is a significant dose-dependent increase in the amount of chondroitin-4-sulfate being produced, confirming the results of Table 2 above that indicate the ability of chondroitinase to stimulate cartilage. Table 3
- Ch-6-S Mean 1.467 1.486 1.539 1.567 1.657 1.602
- Ch-4-S Mean 3.96 4.53 4.7 5.01 5.87 5.83
- the cells used in this later set of experiments are, in fact, believed to be more analogous to the cartilage of the osteoarthritic condition, where more chondroitin-6-sulfate is produced than in normal tissue.
- PG-Lt An anti-aggrecan antibody (PG-Lt), which specifically binds the core protein of aggrecan, was employed to measure the ability of chondroitinase-treated chondrocytes to synthesize aggrecan as part of the new cartilage matrix produced by the stimulated cells.
- the experiments were performed in a similar manner to those described in Example 2, with the exception of the second chondroitinase treatment immediately prior to antibody treatment.
- Figure 1 illustrates, the level of aggrecan expression after 4 days was correlated with the chondroitinase treatment in a dose- dependent manner.
- Explant cultures of articular cartilage provide an excellent model system for studies of cartilage metabolism, since events observed in situ can be replicated by the culture system.
- the objective of this study was to use cartilage explant culture as a model system to determine the effect of chondroitinase ABC digestion of cartilage on the rate of proteoglycan synthesis by the chondrocytes.
- Bovine articular cartilage was isolated and maintained in culture for 48 hours to stabilize the cultures. The explants were then treated with various concentrations of chondroitinase ABC (0 to 1 units/ml) for 3 hours. The explants were washed thoroughly in media (3 times for 1 hour, and then overnight), and then cultured for 4 days. At that time the rate of proteoglycan synthesis (determined by 35s-sulfate incorporation) was determined.
- the analyses show that treatment of articular cartilage with chondroitinase ABC results in a dose-dependent increase in the rate of proteoglycan synthesis. At 0.01 units chondroitinase ABC/ml the proteoglycan synthesis rate was increased by 3.4 fold, and at 0.1 units of chondroitinase ABC/ml the proteoglycan synthesis rate was increased by 22.5 fold. These results show that treatment of articular cartilage with chondroitinase ABC can result in a dramatic increase in the synthesis of cartilage matrix components.
Abstract
The present invention relates to the use of an ECM-altering enzymatic activity, such as a proteoglycanase or a protease, to stimulate the generation of cartilage tissue by inducing chondrocytes to synthesize new cartilage matrix. It has been discovered that treating chondrocytes with an enzymatic activity that modifies the territorial ECM of the cell, especially cell surface proteoglycans, can in and of itself be sufficient to stimulate cartilage production by the chondrocytes. The subject invention can be employed therapeutically to correct or prevent degeneration of connective tissue. For instance, the present method can be used in the treatment of disorders comprising cartilage such as found in a diarthroidal joint (e.g. articular and interarticular cartilage), as well as in the treatment of tendon and ligamental tissues. Such disorders can range from chronic degeneration brought about by disease, overuse, or trauma, to plastic or reconstructive surgery. Moreover, the subject method may also be applied to both the development and implantation of prosthetic devices.
Description
Methods of Repairing Connective Tissues
Background of the Invention
Evolution in mammals, reptiles, birds and fish has developed extraordinarily efficient musculoskeletal systems for generating and controlling motion. However, the musculoskeletal system is not only an efficient system for delivering useful mechanical energy and load support, but is also capable of synthesizing, processing and organizing complex macromolecules to fashion tissues and organs for specific mechanical functions. An important subset of organs of the musculoskeletal system are the joints. Many types of joints exist in the body. Freely moving joints (ankle, elbow, hip, knee, shoulder, and those of the fingers, toes and wrist) are known as diarthrodial or synovial joints. The intervertebral joints of the spine are not diarthrodial joints as they are fibrous and do not move freely. They do, however, provide the flexibility required by the spine.
Diarthrodial joints enable local motion and other activities of daily life to take place. They perform their function so well that we are often not even aware of their existence nor the function they provide until injury strikes or arthritis develops. From an engineering point of view, these natural bearings are very uncommon structures. Under healthy conditions, they function nearly frictionless and remain almost entirely wear-resistant manner throughout our lives. Failure of the bearings surfaces of the body (i.e. articular cartilage), as with engineering bearings, means a failure of these bearings to provide their central functions. In biomedical terms, failure of diarthrodial joints leads to arthritis. The most common form being Osteoarthrisis or Osetoarthrothesis. Repair of arthritic joints means orthopedic surgery to replace the worn-out joints by a prosthesis or by a biological graft. This is an enormous medical and economic problem, with more than thirty million Americans suffering from the disabling disease.
Diarthrodial joints have some common structural features. First, all diarthrodial joints are enclosed in a strong fibrous capsule. Second, the inner surfaces of the joint capsule are lined with a metabolically active tissue, the synovium, which secretes the synovial fluid that lubricates the joint and provides the nutrients required by the avascular cartilage. Third, the articulating bone ends in the joint are lined with a thin layer of hydrated soft tissue known as articular cartilage. These linings, i.e. the synovium and articular cartilage layers, form the joint cavity which contains the synovial fluid. Thus, in animal joints, the synovial fluid, articular cartilage, and the supporting bone form the bearing system which provides the smooth nearly-
frictionless bearing system of the body. While diarthrodial joints are subjected to an enormous range of loading conditions under cyclical conditions, the cartilage surfaces undergo little wear and tear under normal circumstances. Indeed, most human joints must be capable of functioning effectively under very high loads and stresses and at very low operating speeds. These performance characteristics demand efficient lubrication processes to minimize friction and wear of cartilage in the joint. Sever breakdown of the joint cartilage by either biochemical or biomechanical means leads to arthritis and thus arthritis is defined as a failure of the animal bearing system. Finally, the joint is stabilized by, and in motion is controlled by, ligaments and tendons which may be inside or outside the joint capsule.
Hyaline cartilage, as the names implies is glass smooth, glistening and bluish white in appearance, although older or diseased tissue tends to lose this appearance. The most common hyaline cartilage, and the most studied, is the articular cartilage. This tissue covers the articulating surfaces of long boned and siesamoid bones within diarthrodial joints. Articular cartilage is characterized by a particular structural organization. It consists of specialized cells (chondrocytes) embedded in an intercellular material (typically referred to as "cartilage matrix") which is rich in proteoglycans, collagen fibrils, other proteins, and water. Cartilage tissue is neither innervated nor penetrated by the vascular or lymphatic systems. However, in the mature joint of adults, the underlying subchondral bone tissue - which forms a narrow, continuous plate between the bone tissue and the cartilage- is innervated and vascularized. Beneath this bone plate, the bone tissue forms trabeculae, containing the marrow. In immature joints, articular cartilage is underlined by only primary bone trabeculae. A portion of the meniscal tissue in joints (referred to as the "interarticular" cartilage) also consists of cartilage whose make-up is similar to articular cartilage. It is generally believed that because articular cartilage lacks a vasculature, damaged cartilage tissue does not received sufficient or proper stimuli to elicit a repair response.
The menisci of the knee, and other similar structures such as the disc of the temporomandibular joint and the labrum of the shoulder, are specialized fibrocartilagenous structures which perform functions which are vital for normal joint function. They are known to assist the articular cartilage in distributing loads across the joint, assist the ligaments and tendons in providing joint stability, play a major role in shock absorption, and may assist in lubrication of the joint. Damage to these structures can lead to a reduction in joint function and degeneration of the articular cartilage. Surgical removal can result in early onset of osteoarthritis. The menisci, disc and labrum are hydrated fibrocartilage structures composed primarily of collagen (type I) with smaller amounts of other collagens and proteoglycans (including
aggrecan and the smaller, non-aggregating proteoglycans). They contain a sparse population of cells which, like the chondrocytes of cartilage, are responsible for the synthesis and maintenance of this extracellular matrix.
Skeletal ligaments are specialized connective tissues that connect bones.
They serve a passive mechanical function in stabilizing joints and in guiding joint motion. Further, they may have a neurosensory role transporting dynamic information to muscles. Ligaments are composed primarily of type I collagen organized in parallel arrays, with small amounts of other collagens, proteoglycans, elastin and other proteins and glycoproteins. The cells are fibroblastic in the midsubstance, and appear more chondroid at and near the insertion sites. Tendons have a similar structure, with a relatively high concentration of collagen, organized primarily as fibers in parallel. Other components are proteoglycans, elastin and other proteins and glycoproteins. The cells are fibroblastic in nature. The cells of the tendon and ligament are metabolically active and are responsible for the synthesis and maintenance of this extracellular matrix.
Proteoglycans comprise the second largest portion of the organic material in articular cartilage. These macromolecules are composed of a protein core to which are attached a number of covalently bound GAG chains (chondroitin sulfate and keratan sulfate). There are many different types of proteoglycans present in a wide range of tissues throughout the body; presumably, they also have different functions in the various tissues. However, the most extensively studied proteoglycans have been those from articular cartilage because of its role in regulating skeletal growth, joint function and the development of arthritis.
The major proteoglycans present in articular cartilage are the large aggregating type (50-85%) and the large non-aggregating type (10-40%) with distinct small proteoglycans also present. The molecular weights of these proteoglycan monomers range from 1 x 10^ to 4 x 10^ , and they contribute significantly to the mechanical and physicochemical properties of cartilage. These molecules are highly ordered structures with length scales ranging from 10~8 to 10~6 m. First, there is an extended protein core with several distinct regions: an N-terminal region with two globular domains (Gl and G2), a keratan sulfate-rich domain, a longer chondroitin sulfate-rich domain which may also contain some interspersed keratan sulfate and neutral oligosaccharide chains, and a C-terminal globular domain (G3) on the proteoglycan monomer. Aggregates are formed when many proteoglycan monomers bind to a long monofilament chain of hyaluronan via their Gl globular domain. Each proteoglycan-hyaluronan bond is stabilized by a separate globular link protein (mw,
41,000-48,000), and this stabilization is vital in providing additional strength to the molecular network formed by proteoglycans in concentrated solutions. The structure of proteoglycan in cartilage is not uniform. The size of the proteoglycan aggregate depends mainly on the size of the hyaluronate chain and may be as large as 350 x 10^, particularly in fetal cartilage. Differences in chain length and amounts of keratan sulfate and chondroitin sulfate, length of the protein core, and degree of aggregation all contribute to the compositional and structural heterogeneties of proteoglycans within the tissue.
The GAG chains of the proteoglycans provide important physicochemical properties to cartilage. First, chondroitin sulfate (CS:~mw, 20,000) is composed of repeating disaccharide units of glucuronic acid and N- acetylgalactosamine with a sulfate (SO4) group and a carboxyl (COOH) group per disaccharide. Evidence exists indicating that these CS chains are the main determinants of frictional resistance against inter-stitial fluid flow. Keratan sulfate (KS) consists of repeating disaccharide units of galactose and N-acetylglucosamine, again averaging approximately one SO4 group per disaccharide. Keratan sulfate content of proteoglycans increases with age from zero in fetal cartilage to a maximum in aging cartilage. Both proteoglycan content and size decrease with increasing "severity of OA.
In articular cartilage, molecular interactions occur through collagen- collagen covalent cross-link interactions, and proteoglycan-proteoglycan and collagen- proteoglycan non-covalent (electrostatic and mechanical) interactions. The most well- known interactions are the collagen-collagen covalent cross-links. These cross links are important in providing a strong and stiff collagen network. Thus, in the extracellular matrix these two molecular networks (proteoglycan and collagen) must coexist to form a fiber-reinforced composite solid with the collagen network providing the tensile stiffness and strength, and the proteoglycan network providing the compressive stiffness (via the Donnan osmotic pressure, electrostatic repulsion amongst the fixed negative charges and bulk compressive stiffness). The physical interactions between collagen and proteoglycan can arise from two sources: electrostatic and mechanical. First, evidence exists indicating that the negative charge groups on the proteoglycans can interact with the positive charge groups along the collagen fibrils, and hyaluronates of the aggregate do interact with type II, IX and X collagen. Second, evidence of strong frictional interaction between the proteoglycans and the fine collagen network also exists. No covalent bonding exists between collagen fibrils and proteoglycans. In normal cartilaginous tissue, proteoglycans are slowly but continuously turned over, the degraded molecules are released from the
cartilage and are replaced by newly synthesized components. It is the coordinate control of synthesis and degradation of the matrix components by the chondrocytes that maintain normal cartilage. In experimental models of joint disease, for example, there is evidence of charges in the rate of biosynthesis and turnover of proteoglycans, which may contribute to cartilage degeneration. This chondrocyte-mediated degeneration leads to the whole cascade of degenerative bone and connective tissue events that results in osteoarthritis, limb immobilization, and other effects requiring surgical intervention.
Over one million surgical procedures in the United States each year involve cartilage replacement. Current therapies include transplantation with allografts (removing healthy cartilage from a donor, and reimplanting into a joint of the recipient), implantation of artificial polymer or metal prostheses, and surgical removal of old or degenerative cartilage and the surgical treatment of underlying bone to stimulate new cartilage formation. This new cartilage is usually a fibrous cartilage significantly inferior to the hyaline cartilage it is replacing. Other surgical procedures of synovial joints involve the replacement of menisci, ligaments and tendons with biological grafts or artificial tissues. Torn or severed menisci, discs of the temporomandibular joint, labrum of the shoulder, tendons and ligaments often undergo surgical repair. Degenerative loss of articular cartilage, for example, at the acetabular/femoral head artoculation, results in heavy loading of the soft tissue, and can require radical surgery.
Surgical procedures account for only a fraction of the treatment of individuals who suffer from disabling diseases resulting from connective tissue damage and degeneration in synovial joint. Alternative treatment includes conservative treatment (e.g., rest and physical therapy), and treatment is largely directed at symptomatic relief through the use of analgesics and nonsteroidal anti- inflammatory drugs.
There are significant limitations with all present approaches. Artificial prostheses have a limited lifetime, and can fail prematurely. Recurrent replacements of prostheses is not an advisable treatment, and, therefore, the relatively young and active patient is often consigned to slow joint degeneration until the use of prosthetic implants becomes a reasonable clinical option. Prostheses rarely replicate the performance of the original tissue. A prosthesis cannot adapt in response to environmental stress as does a biological tissue, nor can it repair itself. Biological allograft material is in limited supply, appropriate size shape and tissue type are difficult to obtain, and has the risk of carrying infectious diseases. Use of autograft
material compromises the site used for the source tissue (e.g., using patella tendon to replace anterior cruciate ligament), and can only offer this tissue once. Biological graft tissue rarely, if ever, is able to provide a tissue with the same functional properties as the original tissue.
There appear to be genetic predisposition's to degenerate diseases of the connective tissues that exacerbate the effects of sport and other early injury. Even during pregnancy, there can be generalized stress on cartilage resulting from tropic hormone levels meant for softening of the pubic symphysis, and these can be exacerbated by congenital predisposition and prior injury.
There is therefore a need to offer a process that can stimulate the biological repair of the connective tissue, or stop the degeneration or slow the progression of degeneration of cartilage, menisci, tendons and ligaments.
Description of the Drawings
Figure 1 illustrates the dose-dependent synthesis of aggrecan by chondrocytes treated with chondroitin ABC lyase. The binding of an anti-aggrecan antibody (PG-Lt) was measured immediately after chondroitinase treatment ("0 days") and 4 days subsequent. As described below, antibody binding was assessed by EIA techniques utilizing detection of substrate release (absorbance at 405nm).
Summary of the Invention
The present invention relates to the use of an ECM-altering enzymatic activity, such as a proteoglycanase or a protease, to stimulate the generation of cartilage tissue by inducing chondrocytes to synthesize new cartilage matrix. It has been discovered that treating chondrocytes with an enzymatic activity that modifies the territorial ECM of the cell, especially cell surface proteoglycans, can in and of itself be sufficient to stimulate cartilage production by the chondrocytes. The subject invention can be employed therapeutically to correct or prevent degeneration of connective tissue. For instance, the present method can be used in the treatment of disorders comprising cartilage such as found in an diarthroidal joint (e.g. articular and interarticular cartilage), as well as in the treatment of tendon and ligamental tissues. Such disorders can range from chronic degeneration brought about by disease, overuse, or trauma, to plastic or reconstructive surgery. Moreover, the subject method may also be applied to both the development and implantation of prosthetic devices.
Detailed Description of the Invention
Cartilage, ligament, tendon, menisci, disc of tempromanibular joint and labrum of the shoulder are metabolically active connective tissue. They consist of an extracellular matrix (ECM) that contains a population of cells (chondrocytes in hyaline cartilage and the like, and fibrochondrocytes in fibrocartilage, such as meniscal cartilage), wherein the synthesis and maintenance of the tissue are dependent on the appropriate activities of the chondrocytes (or fibrochondrocytes, or other connective tissue cell) associated with it. The metabolic activities involve both anabolic and catabolic events, which include: (a) the synthesis of matrix components, (b) the incorporation and organization of these components into the matrix, and (c) their degradation and loss from the matrix. The chondrocytes are responsible for orchestration of these events, and their appropriate balance results in a maintenance of the cartilage matrix and its biological function. These cells have the capacity to respond to their environment. The effector agents may be soluble mediators (such as growth factors, cytokines, pharmaceutical agents), matrix composition, hydrostatic pressure, and mechanical load. In normal conditions, these responses are designed to maintain a functional matrix. However, some stimulators may result in the cells responding in a manner which degrades the ECM, or in a manner which results in failed repair, and degradation of the ECM occurs.
The present invention relates to the use of an enzymatic activity, such as a chondroitinase, keratanase, hyaluronidase or protease activity, to stimulate production of a connective tissue matrix by the cells within that matrix. By protease activity, we refer specifically to those proteases that do not substantially cleave the collagen matrix. Rather, protease activity refers specifically to those proteases that act only on the proteins of the proteoglycan element of the matrix, and the like.
The present invention arises from the unexpected finding that enzymatically altering the extracellular matrix of a connective tissue cell, particularly of a chondrocyte, has a stimulatory effect on the production of cartilage matrix and other connective tissue matrices by the treated cells. The subject method is applicable in vivo, as for example, in the restoration or remodeling of a connective tissue. This procedure has the potential to slow, stop, or reverse the progression of the degeneration of connective tissue, such as occurs in osteoarthritis, rheumatoid arthritis and other chronic joint disorders. Further, the present method can be used to treat connective tissue which has undergone traumatic injury or excessive wear, or which is the subject of reconstructive/plastic surgery. The subject method is particularly
suitable for application in treatments wherein the cartilage generated is to remain unossified. Moreover, the use of the subject method in healing processes can provide correct regeneration of the connective tissue and thereby reduce the amount of fibrotic tissue that might otherwise occur.
Another aspect of the present method involves the use of such ECM- altering enzymatic activities to stimulate production of cartilage in vitro, such as in the generation of prosthetic devices. A great deal of effort has been exerted over the years to facilitated regeneration and repair of bone and cartilage. Several techniques, including cartilage implants and bone implants and grafts for the remedy of many skeletal disorders and chondrodystropies, can be enhanced by use of the present methods and formulations, both during the formation of the prosthetic and after implantation.
It has been discovered that treating chondrocytes with an enzymatic activity that modifies the territorial ECM of the cell, especially cell surface proteoglycans, can in and of itself be sufficient to stimulate cartilage production by the chondrocytes. The present therapeutic methods have a number of advantages over prior techniques used to repair cartilage. In certain embodiments of the subject method, because of the relatively specific targeting of ECM components of the chondrocyte by an enzymatic activity, such as a chondroitinase, and the concomitant activation of these cells, a tighter regulation of the types of cells stimulated during treatment can be achieved. This is in contrast to the use of general mitogenic agents such as growth factors or cytokines which can elicit responses in a broad range of cells, including cells whose activities can be detrimental to cartilage repair. For example, many mitogens have the effect of stimulating osteogenesis in addition to chondro genesis, and therefore result in induction of bone formation. Thus, it may be advantageous in those circumstances where osteogenic processes are undesirable to treat the tissue in which repair or remodeling of cartilage is desired with a preparation consisting essentially of an ECM-altering enzymatic activity.
The ECM-altering activity useful in the present invention is an enzyme or other catalytic activity which sufficiently alters the extracellular matrix of a chondrocyte, especially the proteoglycans of the territorial matrix of the cell, so as to induce the chondrocytes to synthesize cartilage matrix. In one embodiment, the ECM- altering activity is a proteoglycanase which digests chondroitin sulfate glycosaminoglycan chains of proteoglycans associated with the chondrocytes. Such enzymatic activities can also digest other GAG chains, including dermatan sulfate and hyaluronate. In an illustrative embodiment, the proteoglycanase is a dissacharidase,
such as a chondroitin lyase (chondroitinase), which can catalyze the depolymerization of chondroitin sulfate GAGs, particularly chondroitin-6-sulfate and chondroitin-4- sulfate, by the elimination of 1,4 hexosaminidic bonds. For example, chondroitin ABC lyase (EC 4.2.2.4) is a particularly useful chondroitinase activity which catalyzes depolymerization of a glycosaminoglycan containing 1,4-b-D-hexosaminyl and 1,3-b- D-glucuronosyl or 1,3-a-D-iduronosyl linkages by elimination of D-4,5-D-glucuronate residues from the glycosaminoglycan. Other proteoglycanase activities useful in the present invention include chondroitin AC lyase (EC 4.2.2.5), Hyaluronoglucosaminidase (EC 3.2.1.35), Hyaluronoglucuronidase (EC 3.2.1.36), β- N-acetylglucosaminidase (EC 3.2.2.30), Hyaluronate lyase (EC 4.2.2.1),
Chondroitinsulphatase (EC 3.1.6.4), Chondro-4-sulphatase (EC 3.1.6.9), Chondro-6- sulphatase (EC 3.1.6.10). Further examples of proteoglycanases useful in the subject method can be found, for example, in Endo et al. (1992) Tanpakushitsu Kakusan Koso 37:2008-2011; Misevic et al. (1990) J Cell Biochem. 43:307-314; Gharbia et al. (1993) FEMS Immunol. Med. Microbiol. 6:139-145; Kresse et al. (1987) Adv. Enzymol. Relat. Areas Mol. Biol. 60: 127-311 ; and Conzelmann et al. (1987) Adv. Enzymol. Relat. Areas Mol. Biol. 60:89-216.
The present invention further contemplates the use of other hydrolases or lyases, including engineered enzymes and catalytic antibodies, which alter the extracellular matrix of the chondrocytes so as to stimulate these cell to initiate cartilage matrix synthesis. One class of enzymes of use in the subject method are proteases which act to cleave the core protein of chondrocyte-bound proteoglycans. For example, in an illustrative embodiment, the chondrocytes are contacted with a trypsin-like activity able to release cell surface proteoglycans by cleaving the core protein of a proteoglycan, such as aggrecan.
In a preferred embodiment, the ECM-altering activity acts primarily on the proteoglycan matrix and leaves any collagen matrix surrounding the chondrocyte substantially intact. By substantially intact, it is meant that no more than 20% of the collagen matrix in the treatment area is enzymatically altered, and more preferably, no more than 5% is altered, and most preferably, no more than 2%. It can be especially advantageous to avoid use of enzymes which, particularly at high concentration, decrease the tensile strength of the collagen matrix in the treatment area.
Furthermore, the ECM-altering agent can be generated as a chimeric protein comprising an additional moiety that binds a component of the extracellular matrix. Such a chimeric molecule can be useful in circumstances wherein diffusion of the enzyme from a treatment site is undesirable, and will function to such an end by
virtue of localizing the chimeric molecule at or proximate a treatment site. A ECM- altering enzyme of this embodiment can be generated as the product of a fusion gene, or by chemical cross-linking.
A number of proteins have been characterized from the extracellular matrix (ECM) of connective tissues that will support the localization of a chimeric ECM-altering agent, such as a chondroitinase-containing chimeric protein, at a target site. One example of a well characterized protein is fibronectin. Fibronectin is a large adhesive glycoprotein with multiple functional domains. Several of these domains have matrix attachment activity. For example, one of these is a single "type-Ill repeat" which contains a tetrapeptide sequence R-G-D-S (Pierschbacher et al. (1984) Nature 309:30-3; and Kornblihtt et al. (1985) EMBO 4:1755-9). Peptides as small as pentapeptides containing these amino acids are able to support attachment to a cell through binding ECM components (Ruoslahti et al. (1987) Science 238:491-497; Pierschbacheret al. (1987) J. Biol. Chem. 262:17294-8.; Hynes (1987) Cell 48:549-54; and Hynes (1992) Cell 69:11-25). In fact, several companies have commercialized products based on this cell attachment sequence for use as reagents in cell culture and various biomaterials applications. See, for example, recent catalogs from Telios Pharmaceutical, BRL, Stratagene, Protein Polymer Technologies etc., as well as U.S. Patent Nos. 4,517,686; 4,589,881; 4,578,079; 4,614,517; 4,661,111; and 4,792,525. In an illustrative embodiment, an RGDS sequence is added to chondroitin ABC lyase to produce a chondroitinase activity having additional ECM localizing characteristics.
The ECM-altering enzyme, or pharmaceutically acceptable salts thereof, may be conveniently formulated for administration with a biologically acceptable medium, such as water, buffered saline, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like) or suitable mixtures thereof. The optimum concentration of the active ingredients in the chosen medium can be determined empirically, according to procedures well known to medicinal chemists. As used herein, "biologically acceptable medium" includes any and all solvents, dispersion media, and the like which may be appropriate for the desired route of administration of the pharmaceutical preparation. The use of such media for pharmaceutically active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the activity of the enzyme, its use in the pharmaceutical preparation of the invention is contemplated. Suitable vehicles and their formulation inclusive of other proteins are described, for example, in the book Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences. Mack Publishing Company, Easton, Pa., USA 1985). These vehicles include injectable "deposit formulations". Based on the above, the pharmaceutical formulation includes,
although not exclusively, solutions or a freeze-dried powder of at least one ECM- altering enzyme in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered media at a suitable pH and isosmotic with physiological fluids. For illustrative purposes only and without being limited by the same, possible composition of formulations which may be prepared in the form of solutions for the treatment of connective tissues with an ECM-altering activity are given in the della Valle U.S. Patent No. 5,218,094. In the case of freeze-dried preparations, supporting excipients such as, but not exclusively, mannitol or glycine may be used and appropriate buffered solutions of the desired volume will be provided so as to obtain adequate isotonic buffered solutions of the desired pH. Similar solutions may also be used for the pharmaceutical compositions of the enzyme in isotonic solutions of the desired volume and include, but not exclusively, the use of buffered saline solutions with phosphate or citrate at suitable concentrations so as to obtain at all times isotonic pharmaceutical preparations of the desired pH, for example, neutral pH.
Methods of introducing the ECM-altering activity at the site of treatment include, but are not limited to, intra-articular, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, oral, topical, and intranasal. Methods of introduction may also be provided by rechargable or biodegradable devices. Various slow release polymeric devices have been developed and tested in vivo in recent years for the controlled delivery of drugs, including proteinacious biopharmaceuticals. A variety of biocompatible polymers (including hydrogels), including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of the enzymatic agent at a particular target site.
An essential feature of certain embodiments of the implant can be the linear release of the ECM-altering enzyme, which can be achieved through the manipulation of the polymer composition and form. By choice of monomer composition or polymerization technique, the amount of water, porosity and consequent permeability characteristics can be controlled. The selection of the shape, size, polymer, and method for implantation can be determined on an individual basis according to the disorder to be treated and the individual patient response. The generation of such implants is generally known in the art. See, for example, Concise Encyclopedia of Medical & Dental Materials, ed. by David Williams (MIT Press: Cambridge, MA, 1990); and the Sabel et al. U.S. Patent No. 4,883,666. In another embodiment of an implant, a source of cells producing the ECM-altering agent, or a solution of hydrogel matrix containing a purified ECM-altering enzyme, is encapsulated in implantable hollow fibers. Such fibers can be pre-spun and
subsequently loaded with both agents (Aebischer et al. U.S. Patent No. 4,892,538; Aebischer et al. U.S. Patent No. 5,106,627; Hoffman et al. (1990) Expt. Neurobiol. 110:39-44; Jaeger et al. (1990) Prog. Brain Res. 82:41-46; and Aebischer et al. (1991) J. Biomech. Eng. 113:178-183), or can be co-extruded with a polymer which acts to form a polymeric coat about a source the enzyme (Lim U.S. Patent No. 4,391,909; Sefton U.S. Patent No. 4,353,888; Sugamori et al. (1989) Trans. Am. Artif Intern. Organs 35:791-799; Sefton et al. (1987) Biotehnol. Bioeng. 29:1135-1143; and Aebischer et al. (1991) Biomaterials 12:50-55).
Where the ECM-altering enzyme is a chondroitin ABC lyase, the therapeutically effective amount of the enzyme will typically be in the range of .005- 200 Units/ml, and, more preferably, in the range of .1-20 Units/ml. As used herein with respect to the chondroitinase activity, the term Unit is defined as the quantity of chondroitinase that catalyzes the formation of 1 mmole of unsaturated disaccharide from chondroitin-6-sulfate per min. at 37°C, pH 8.0.
The present invention makes available effective therapeutic methods and compositions for restoring cartilage function to a connective tissue. Such methods are useful in, for example, the repair of defects or lesions in cartilage tissue which is the result of degenerative wear such as that which results in arthritis, as well as other mechanical derangements which may be caused by trauma to the tissue, such as a displacement of torn meniscus tissue, meniscectomy, a laxation of a joint by a torn ligament, malignment of joints, bone fracture, or by hereditary disease. The present reparative method is also useful for remodeling cartilage matrix, such as in plastic or reconstructive surgery, as well as periodontal surgery. The present method may also be applied to improving a previous reparative procedure, for example, following surgical repair of a meniscus, ligament, or cartilage. It may prevent the onset or exacerbation of degenerative disease if applied early enough after trauma.
In one embodiment of the present invention, the subject method is used therapeutically to generate a cartilage repair response in a connective tissue by stimulating chondrocytes (or fibrochondrocytes) embedded in the tissue to synthesize cartilage matrix. Such connective tissues as articular cartilage, interarticular cartilage (menisci), costal cartilage (connecting the true ribs and the sternum), ligaments, and tendons are particularly amenable to treatment in reconstructive and/or regenerative therapies using the subject method. As used herein, regenerative therapies include treatment of degenerative states which have progressed to the point of which impairment of the tissue is obviously manifest, as well as preventive treatments of
tissue where degeneration is in its earliest stages or imminent. The subject method can further be used to prevent the spread of mineralisation into fibrous tissue.
In an illustrative embodiment, the subject method is used to treat cartilage of a diarthroidal joint, such as knee, an ankle, an elbow, a hip, a wrist, a knuckle of either a finger or toe, or a temperomandibular joint. The treatment can be directed to the meniscus of the joint, to the articular cartilage of the joint, or both. To further illustrate, the subject method can be used to treat a degenerative disorder of a knee, such as which might be the result of traumatic injury (e.g., a sports injury or excessive wear) or osteoarthritis. An injection of an ECM-altering agent into the joint with, for instance, an arthroscopic needle, can be used to treat the afflicted cartilage. In some instances, the injected agent can be in the form of a hydro gel or other slow release vehicle described above in order to permit a more extended and regular contact of the agent with the treated tissue.
Moreover, as described above, the ECM-altering enzyme can be formulated and delivered to a specific location. For instance, slow release polymers can be localized to a particular treatment area of a mensical disc. To illustrate, degenerative changes are prominent in the triangular cartilage disc of the wrist joint of elderly people. The degeneration is more frequent and advanced on the ulnar side of the disc, perhaps because the biomechanical forces are more intense on that side. The degeneration affects the avascular portions of the disc but not the vascularized edges. Thus, an ECM-altering enzyme can be localized to the center of the ulnar face of the disc to enhance reparative process in that portion of the disc without substantially altering the integrity of the rest of the disc.
In another illustrated embodiment, the subject method can be used to treat cartilage of the costal sternum. After open chest surgery, such treatment can be opportunely employed in speeding reattachment of severed ribs to the sternum, as well as to decrease the amount of fibrotic tissue generated during healing.
In yet another embodiment of the subject method, an ECM-altering agent is contacted with cartilage of the pubic symphysis to enhance reattachment of the hip bones. For example, such treatments can be utilized in a female patient after delivery of a baby in order to mediate healing of the pubic symphysis which has undergone an intracartilaginous fissure from the degeneration of hyaline cartilage before and during labor.
In still a further embodiment, the subject method is applied to prevent replacement of hyaline cartilage after injury or other degenerative disorders, by other kinds of connective tissue such as fibroses or fibrous cartilage, as well as to prevent ossification of cartilaginous tissues. For example, the present invention can be used in the treatment of disorders in which cartilage is replaced by bone Treatment of this tissue by the subject method can inhibit the spread of mineralisation into the cartilage tissue by stimulating production of new cartilage matrix which turns over or otherwise replaces cartilage which is undergoing osteogenic processes.
The present invention further contemplates the use of the subject method in the field of cartilage transplantation and prosthetic device therapies. To date, the growth of new cartilage from either transplantation of autologous or allogenic cartilage has been largely unsuccessful. Problems arise, for instance, because the characteristics of cartilage and fibrocartilage varies between different tissue: such as between articular, meniscal cartilage, ligaments, and tendons, between the two ends of the same ligament or tendon, and between the superficial and deep parts of the tissue. The zonal arrangement of these tissues may reflect a gradual change in mechanical properties, and failure occurs when implanted tissue, which has not differentiated under those conditions, because the implant lacks of the ability to appropriately respond. For instance, when meniscal cartilage is used to repair anterior cruciate ligaments, the tissue undergoes a metaplasia to pure fibrous tissue.
By promoting chondrogenesis, the present invention can be used to particularly addresses this problem, by causing the implanted cells to become more adaptive to the new environment and effectively resemble hypertrophic chondrocytes of an earlier developmental stage of the tissue. Thus, the action of chondrogensis in the implanted tissue, as provided by the subject method, and the mechanical forces on the actively remodeling tissue will synergize to produce an improved implant more suitable for the new function to which it is to be put.
In similar fashion, the subject method can be applied to enhance remodeling of ligaments or tendons that are surgically shortened. For example, the present invention can be used to treat temperomandibular joint dysfunction (TMJ) either in regenerating the disc (as described for other joints above) or in the repair or replacement of the ligamental tissue which articulates the disc with the surrounding skeletal bones to correctly position the disc on the head of the condyle. For instance, in certain forms of TMJ, the ligaments have been stretched such that the interarticular disc is positioned either anterior or posterior to the condyle head. Surgical procedures to shorten the ligaments have been used to correct this deformity. The subject method
can be used in the treatment of the shortened ligament to provide an improved ligament having zonal patterning that has advantageously been developed by the active remodeling of the "new" ligament by chondrocyte activation. Moreover, the present invention can prevent the occurrence of fibrotic tissue in the shortened ligament.
In similar fashion, the subject method can be applied to enhancing both the generation of prosthetic cartilage devices and to their implantation. The need for improved treatment has motivated research aimed at creating new cartilage that is based on collagen-glycosaminoglycan templates (Stone et al. (1990) Clin Orthop Relat Red 252:129), isolated chondrocytes (Grande et al. (1989) J Orthop Res 7:208; and Takigawa et al. (1987) Bone Miner 2:449), and chondrocytes attached to natural or synthetic polymers (Walitani et al. (1989) J Bone Jt Surg 71B:74; Vacanti et al. (1991) Plast Reconstr Surg 88:753; von Schroeder et al. (1991) J Biomed Mater Res 25:329; Freed et al. (1993) J Biomed Mater Res 27:11; and the Vacanti et al. U.S. Patent No. 5,041,138). For example, chondrocytes can be grown in culture on biodegradable, biocompatible highly porous scaffolds formed from polymers such as polyglycolic acid, polylactic acid, agarose gel, or other polymers which degrade over time as function of hydrolysis of the polymer backbone into innocuous monomers. The matrices are designed to allow adequate nutrient and gas exchange to the cells until engraftment occurs. The cells can be cultured in vitro until adequate cell volume and density has developed for the cells to be implanted. One advantage of the matrices is that they can be cast or molded into a desired shape on an individual basis, so that the final product closely resembles the patient's own ear or nose (by way of example), or flexible matrices can be used which allow for manipulation at the time of implantation, as in a joint.
In one embodiment of the subject method, the implants are contacted with an ECM-altering activity during the culturing process, such as a chondroitinase, in order to further stimulate cartilage matrix production within the implant. In such as manner, the cultured cells continue to maintain a phenotype typical of a chondrogenic cell (i.e. hypertrophic), rather than mature chondrocytes, and hence continue the population of the matrix and production of cartilage tissue.
In another embodiment, the implanted device is treated with an ECM- altering activity in order to actively remodel the implanted matrix so as to make it more suitable for its intended function. As set out above with respect to tissue transplants, the artificial transplants suffer from the same deficiency of not being derived in a setting which is comparable to the actual mechanical environment in
which the matrix is implanted. The activation of the chondrocytes in the matrix by the subject method can allow the implant to acquire characteristics similar to the tissue for which it is intended to replace.
In yet another embodiment, the present invention is used to enhance attachment of prosthetic devices. To illustrate, the subject method can be used in the implantation of a periodontal prosthesis, wherein the treatment of the surrounding connective tissue stimulates formation of periodontal ligament about the prosthesis, as well as inhibits formation of fibrotic tissue proximate the prosthetic device.
The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.
Example 1
This experiment was designed to determine the cytotoxicity of chondroitinase for bovine articular cartilage cells in sub-confluent primary culture. These cells were pre- incubated for 48 hours in standard wells in Ham's F-12 medium with and without 10% fetal bovine serum. The medium was removed and replaced with the same medium containing no chondroitinase ABC (control) or from 0.5-00005 units/ml. of chondroitinase ABC. The cells were incubated for 48 hours, fixed, and counted. The results of this experiment are presented in Table One.
Table 1
Cytoxicity of Chondroitinase ABC
Chondroitinase ABC Cells (units/ml) (number/well)
Serum (-) 0 70.3 ± 3.3
0.00005 63.3 ± 3.9
0.0005 53.0 ± 5.1
0.005 43.3 ± 4.8
0.05 41.0 ± 3.6
0.5 48.7 ± 7.8
Serum (+) 0 96.3 ± 21.7
0.00005 108.7 ± 11.7
0.0005 87.0 ± 4.5
0.005 94.3 ± 9.0
0.05 91.7 ± 9.6
0.5 100.3 ± 10.3
The cell number within each major group (serum + and serum -) are not significantly different. Two main conclusions are drawn from these data: 1) The concentrations of chondroitinase ABC added to these cells are not toxic; the cells within each group survived under all conditions, and 2) The presence of serum is not deleterious to the experimental conditions.
Example 2
Further experiments were designed to examine the effect of chondroitinase on the activities of chondrocytes. In these experiments the production of chondroitin-4-sulfate was used as a marker of cartilage proteoglycan production. This form of chondroitin sulfate is the principal form produced by active cartilage- producing chondrocytes, and is the principal form found in the proteoglycan associated with cartilage. As a control the production of chondroitin-6-sulfate was evaluated. This form of chondroitin is found as the principal form in fibroblasts and in fibroblast-like chondrocyte revertents. The primary difference between the two parallel experiments was the age of the culture before exposure to chondroitinase, In one instance, the cells represented a primary culture while in the other the cells were put through 5 passages. In the latter, as a consequence of the multiple passages, a certain percentage of the chondroblasts revert to a fibroblast-like phenotype. That is, while still retaining some cartilage ECM capacity, they also behave like fibroblast. For example, these cells begin synthesizing large quantities of chondroitin-6-sulfate containing proteoglycans.
Chondroitinase ABC was a derivative of the bacterium Proteus vulgaris obtained from one of two sources, Seikagaku America and Taiyo Fishery Co., Ltd. Anti proteoglycan specific for one of chondroitin-6-sulfate or chondroitin-4-sulfate were obtained from ICN. These mouse monoclonal antibodies are able to recognize epitopes of the core protein of cartilage proteoglycan normally containing one of either chondroitin-6-sulfate or 4-sulfate, respectively. Anti-mouse IgG goat-biotin was also purchased from ICN. Streptavidin-Alkaline phosphatase was purchased fro
GIBCO. p-Nitrophenylphosphate was used as the substrate for the enzyme reaction. The washing and sample buffer was a mixture of PBS and 0.05% Tween 20.
Chondrocytes from bovine articular cartilage were removed from the extracellular matrix (ECM) by dissolving the ECM with collagenase. The were placed in Ham's medium containing fetal bovine serum (see Example 1) and cultured in 100mm petri dishes for either three weeks, with three passages into fresh medium (set #1) or for five weeks and five passages (set #2).
At the end of the three week or five week period, aliquots from each culture of 3x10^ cells were inoculated into individual wells of a standard 96-well plate. After three days, the cultures were rinsed gently with physiological buffered saline (PBS), and incubated with from 0 - 0.5 units per ml. of chondroitinase ABC for 20 minutes. After 20 minutes, the medium containing chondroitinase was replaced with normal medium. Each culture was then maintained in the regular medium for three days.
To obtain cell counts, wells and the number of cells in individual wells determined after removing the cells from the wells by trypsinization. The remaining cultures (those to be used for the Elisa experiments) were first washed with PBS and then fixed with 2% paraformaldehyde in cacodylate buffer. The specimens were stored at 4 ° C until ready for the Elisa experiments.
In order to challenge the monoclonal antibodies after fixation, and to determine if the cells were damaged by the live incubation with chondroitin sulfate, the cultures were treated for one (1 ) hour at 37 ° C with 0.05 units/ml albumin (BSA), pH 8.0. (BSA was added as a protease inhibitor to prevent the disruption of the core protein).
The first antibody (e.g. directed to the proteoglycan) was added to the plates and incubated for eighteen hours at 4° C. After incubation, the wells were washed with rinsing buffer three times before the addition of the second antibody. The second antibody (Goat anti-mouse IgG-biotin conjugate) was added to the wells, and the cells were incubated for two hours at room temperature. The wells were then washed with rinsing buffer three times before the addition of the phosphatase- streptavidin conjugate, and incubated for two hours. The plates were then washed three times with rinsing buffer before enhancement. For substrate level enhancement the plates were treated with 0.1% para-nitrophenylphosphate in buffer containing 22 mmol/1 sodium carbonate, 28 mmol/1 sodium bicarbonate, and 1 mmol/1 magnesium
chloride (pH 9.8) for 30 minutes. After enhancement the optical density at 405 nm was measured for each of the wells.
Table 2
The Effect of Chondroitinase on Chondrocytes
Chondroitinase
ABC 0 0.005 0.01 0.05 0.5
(units/ml.)
Ch-6-S Mean 0.648 0.564 0.640 0.631 0.658
SD 0.044 0.062 0.018 0.016 0.013
% deviation - -12 -1 -3 +2 from 0 cone.
Ch-4-S Mean 0.248 0.247 0.268 0.297 0.327
SD 0.007 0.013 0.018 0.018
% deviation - 0 +8 +20 +32 from 0 cone.
Cell Mean 2.93 3.34 2.81 2.75 2.89
Number x SD 0.16 0.59 0.12 0.27 0.18 10,000/well
Table 2 illustrates the results of the chondroitinase treatment of the set #1 cells. The data indicates that the production of proteoglycan comprising chondroitin-4-sulfate increases with increasing concentration of chondroitinase ABC. Conversely, the proteoglycan comprising chondroitin-6-sulfate was not significantly altered with chondroitin ABC treatment. This experiment demonstrates that chondrocytes are stimulated to produce new cartilage proteoglycan.
Table 3 illustrates the results of the experiment with the older chondrocyte primary culture (set #2). Additionally, there is a small increase in the amount of chondroitin-6-sulfate with increased doses of chondroitinase, presumably resulting from the activity of chondrocytes that have reverted to fibroblasts. There is a significant dose-dependent increase in the amount of chondroitin-4-sulfate being produced, confirming the results of Table 2 above that indicate the ability of chondroitinase to stimulate cartilage.
Table 3
The Effect of Chondroitinase on chondrocytes and presumptive fibroblast revertants.
Chondroitinase 0 0.005 0.01 0.05 0.1 0.5 ABC (units/ml)
Ch-6-S Mean 1.467 1.486 1.539 1.567 1.657 1.602
SD 0.024 0.024 0.016 0.025 0.036 0.028
% deviation 1 4.9 6.8 13 9.2 from 0 cone.
Ch-4-S Mean 3.96 4.53 4.7 5.01 5.87 5.83
SD 0.02 0.026 0.027 0.027 0.003 0.016
% deviation - 4 18.6 26.5 48.2 47.2 from 0 cone.
Cell Number Mean 3.3 3.1 3.1 3.1 3.3. 3.3 x 10,000/ SD .2 .1 .2 .2 .1 .1 well
The cells used in this later set of experiments are, in fact, believed to be more analogous to the cartilage of the osteoarthritic condition, where more chondroitin-6-sulfate is produced than in normal tissue.
Example 3
An anti-aggrecan antibody (PG-Lt), which specifically binds the core protein of aggrecan, was employed to measure the ability of chondroitinase-treated chondrocytes to synthesize aggrecan as part of the new cartilage matrix produced by the stimulated cells. The experiments were performed in a similar manner to those described in Example 2, with the exception of the second chondroitinase treatment immediately prior to antibody treatment. As Figure 1 illustrates, the level of aggrecan expression after 4 days was correlated with the chondroitinase treatment in a dose- dependent manner.
Example 4
Explant cultures of articular cartilage provide an excellent model system for studies of cartilage metabolism, since events observed in situ can be replicated by the culture system. The objective of this study was to use cartilage explant culture as a model system to determine the effect of chondroitinase ABC digestion of cartilage on the rate of proteoglycan synthesis by the chondrocytes.
Bovine articular cartilage was isolated and maintained in culture for 48 hours to stabilize the cultures. The explants were then treated with various concentrations of chondroitinase ABC (0 to 1 units/ml) for 3 hours. The explants were washed thoroughly in media (3 times for 1 hour, and then overnight), and then cultured for 4 days. At that time the rate of proteoglycan synthesis (determined by 35s-sulfate incorporation) was determined.
The analyses show that treatment of articular cartilage with chondroitinase ABC results in a dose-dependent increase in the rate of proteoglycan synthesis. At 0.01 units chondroitinase ABC/ml the proteoglycan synthesis rate was increased by 3.4 fold, and at 0.1 units of chondroitinase ABC/ml the proteoglycan synthesis rate was increased by 22.5 fold. These results show that treatment of articular cartilage with chondroitinase ABC can result in a dramatic increase in the synthesis of cartilage matrix components.
All of the above-cited references and publications are hereby incorporated by reference.
Equivalents
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific methods and reagents described herein. Such equivalents are considered to be within the scope of this invention and are covered by the following claims.
What is claimed is:
Claims
1. A method for eliciting a repair response in a damaged connective tissue comprising, treating the tissue with a therapeutically effective amount of an enzymatic activity which alters a proteoglycan component of the extracellular matrix of chondrocytes present in the tissue and thereby stimulates the chondrocytes to produce new cartilage matrix.
2. The method of claim 1, wherein the enzymatic activity comprises a proteoglycanase which depolymerizes a glycosaminoglycan chain of the proteoglycan component.
3. The method of claim 1, wherein the proteoglycanase is a chondroitin ABC lyase.
4. The method of claim 3, wherein the chondroitin ABC lyase is EC
4.2.2.4.
5. The method of claim 1, wherein the enzymatic activity comprises a protease which cleaves a peptide bond of a core polypeptide sequence of the proteoglycan component.
6. The method of claim 1, wherein the proteoglycan component comprises aggrecan.
7. The method of claim 1, wherein the enzymatic activity does not substantially enzymatically alter any collagen matrix component of the chondrocyte.
8. The method of claim 1, wherein the tissue comprises cartilage.
9. The method of claim 8, wherein the cartilage is of a diarthroidal joint.
10. The method of claim 1, wherein the tissue comprises a tendon.
11. The method of claim 1, wherein the tissue comprises a ligament.
12. The method of claim 1, wherein the cartilage matrix forms hyaline cartilage.
13. The method of claim 1, wherein the damage is the result of a chronic joint disorder.
14. The method of claim 13, wherein the chronic joint disorder is selected from a group consisting of osteoarthritis and temperomandibular joint dysfunction.
15. The method of claim 1 , wherein the damage is the result of traumatic injury to the tissue.
16. The method of claim 1, wherein the damage is the result of plastic surgery or reconstructive surgery.
17. The method of claim 16 wherein the reconstructive surgery comprises implantation of a prosthesis and the method stimulates formation of connective tissue with the prosthesis and inhibits formation of fibrotic tissue proximate the prosthesis.
18. A method for stimulating a repair response in cartilage of a diarthroidal joint comprising treating the cartilage with an amount of a proteoglycanse activity sufficient to stimulate synthesis of new cartilage matrix by chondrocytes present in the cartilage.
19. The method of claim 18, wherein the cartilage is articular cartilage.
20. The method of claim 18, wherein the cartilage is interarticular cartilage.
21. The method of claim 18, wherein the diarthrodial joint is selected from a group consisting of a knee, an ankle, an elbow, a hip, a shoulder, a wrist, a knuckle of a finger, a knuckle of a toe, and a temperomandibular joint.
22. The method of claim 18, wherein the newly synthesized cartilage matrix comprises cartilage-specific proteoglycans.
23. The method of claim 18, further comprising treating a synovial fluid of the diarthroidal joint with a therapeutically effective amount of the proteoglycanase activity to depolymerization glycosaminoglycans of proteoglycans contained in the synovial fluid.
24. The method of claim 18, wherein the proteoglycanase is a chondroitin ABC lyase.
25. The method of claim 24, wherein the chondroitin ABC lyase is EC
4.2.2.4.
26. A method for stimulating the generation of a connective tissue comprising treating chondrocytes with an enzymatic activity which alters a proteoglycan component of the extracellular matrix of the chondrocyte, thereby inducing the chondrocytes to synthesize cartilage matrix.
27. The method of claim 26, wherein the enzymatic activity comprises a proteoglycanase which depolymerizes a glycosaminoglycan chain of the proteoglycan component.
28. The method of claim 26, wherein the proteoglycanase is a chondroitin ABC lyase.
29. The method of claim 28, wherein the chondroitin ABC lyase is EC 4.2.2.4.
30. The method of claim 26, wherein the enzymatic activity comprises a protease which cleaves a peptide bond of a core polypeptide sequence of the proteoglycan component.
31. The method of claim 26, wherein the enzymatic activity does not substantially enzymatically alter any collagen matrix component of the chondrocyte.
32. The method of claim 26, wherein the chondrocytes are being cultured in vitro.
33. The method of claim 32, wherein in vitro culture of chondrocytes comprises a prosthetic device for implantation.
34. The method of claim 33, wherein the prosthetic device is an artificial meniscus.
35. The method of claim 33, wherein the prosthetic device is an artificial tendon.
-25-
36. The method of claim 33, wherein the prosthetic device is an artificial ligament.
37. A chimeric chondroitinase activity comprising a chondroitin ABC lyase activity covalently linked to a matrix binding domain which specifically binds an territorial extracellular matrix component (ECM) of a chondrocyte and thereby sequesters the chondroitin ABC lyase to the ECM of the chondrocyte, wherein the matrix binding domain is not naturally associated with the chondroitin ABC lyase.
38. The chimeric chondroitinase of claim 37, wherein the chondroitinase
ABC lyase and the matrix binding domain are present together in a single polypeptide chain fusion protein.
39. The chimeric chondroitinase of claim 37, wherein the matrix binding domain comprises a fibronectin RGDS amino acid sequence.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU11765/95A AU1176595A (en) | 1993-11-12 | 1994-11-14 | Methods of repairing connective tissues |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15047893A | 1993-11-12 | 1993-11-12 | |
US08/150,478 | 1993-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995013091A1 true WO1995013091A1 (en) | 1995-05-18 |
Family
ID=22534708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/013030 WO1995013091A1 (en) | 1993-11-12 | 1994-11-14 | Methods of repairing connective tissues |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1176595A (en) |
WO (1) | WO1995013091A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996001648A1 (en) * | 1994-07-08 | 1996-01-25 | Ibex Technologies R And D, Inc. | Attenuation of wound healing processes |
WO1998051788A2 (en) * | 1997-05-12 | 1998-11-19 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Method and construct for inhibition of cell migration |
WO2001039795A2 (en) * | 1999-12-02 | 2001-06-07 | Ibex Technologies, Inc. | Attenuation of fibroblast proliferation |
WO2002059289A1 (en) * | 2001-01-23 | 2002-08-01 | Hans-Knöll-Institut für Naturstoff-Forschung e.V. | Use of microbial hyaluronate lyase for softening connective tissue |
WO2004017044A3 (en) * | 2002-08-15 | 2004-09-10 | Acorda Therapeutics Inc | Chimeric protein |
EP1839671A2 (en) * | 1999-12-02 | 2007-10-03 | BioMarin Pharmaceutical Inc. | Attenuation of fibroblast proliferation |
US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
US8183350B2 (en) | 2002-05-04 | 2012-05-22 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
US8226941B2 (en) | 2004-05-18 | 2012-07-24 | Acorda Therapeutics, Inc. | Methods of purifying chondroitinase and stable formulations thereof |
US8236302B2 (en) | 2005-09-26 | 2012-08-07 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
US8404232B2 (en) | 2006-10-10 | 2013-03-26 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
US8906363B2 (en) | 2003-05-16 | 2014-12-09 | Acorda Therapeutics, Inc. | Fusion proteins for the treatment of CNS |
EP2354155B1 (en) * | 2003-05-16 | 2017-05-03 | Acorda Therapeutics, Inc. | Fusion Proteins for Treatment of CNS |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0355831A2 (en) * | 1988-08-24 | 1990-02-28 | Seikagaku Kogyo Co., Ltd. | Purification of glycosaminoglycan degrading enzymes |
WO1991016070A1 (en) * | 1990-04-16 | 1991-10-31 | Bethesda Eye Institute | Enzymatic disinsertion of vitreous body |
WO1992013565A1 (en) * | 1991-01-31 | 1992-08-20 | Shaw, Robert, Francis | Growth factor containing matrix for the treatment of cartilage lesions |
EP0576294A2 (en) * | 1992-06-26 | 1993-12-29 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Chondroitinase, process for preparing the same, and pharmaceutical composition comprising the same |
-
1994
- 1994-11-14 AU AU11765/95A patent/AU1176595A/en not_active Abandoned
- 1994-11-14 WO PCT/US1994/013030 patent/WO1995013091A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0355831A2 (en) * | 1988-08-24 | 1990-02-28 | Seikagaku Kogyo Co., Ltd. | Purification of glycosaminoglycan degrading enzymes |
WO1991016070A1 (en) * | 1990-04-16 | 1991-10-31 | Bethesda Eye Institute | Enzymatic disinsertion of vitreous body |
WO1992013565A1 (en) * | 1991-01-31 | 1992-08-20 | Shaw, Robert, Francis | Growth factor containing matrix for the treatment of cartilage lesions |
EP0576294A2 (en) * | 1992-06-26 | 1993-12-29 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Chondroitinase, process for preparing the same, and pharmaceutical composition comprising the same |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996001648A1 (en) * | 1994-07-08 | 1996-01-25 | Ibex Technologies R And D, Inc. | Attenuation of wound healing processes |
WO1998051788A2 (en) * | 1997-05-12 | 1998-11-19 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Method and construct for inhibition of cell migration |
WO1998051788A3 (en) * | 1997-05-12 | 1999-05-20 | Tno | Method and construct for inhibition of cell migration |
EP1839671A2 (en) * | 1999-12-02 | 2007-10-03 | BioMarin Pharmaceutical Inc. | Attenuation of fibroblast proliferation |
WO2001039795A2 (en) * | 1999-12-02 | 2001-06-07 | Ibex Technologies, Inc. | Attenuation of fibroblast proliferation |
WO2001039795A3 (en) * | 1999-12-02 | 2001-12-27 | Ibex Tech Inc | Attenuation of fibroblast proliferation |
JP2004504262A (en) * | 1999-12-02 | 2004-02-12 | アイベックス テクノロジーズ, インコーポレイテッド | Attenuated fibroblast proliferation |
EP1839671A3 (en) * | 1999-12-02 | 2007-10-31 | BioMarin Pharmaceutical Inc. | Attenuation of fibroblast proliferation |
US7056711B2 (en) | 1999-12-02 | 2006-06-06 | Denholm Elizabeth M | Attenuation of fibroblast proliferation |
WO2002059289A1 (en) * | 2001-01-23 | 2002-08-01 | Hans-Knöll-Institut für Naturstoff-Forschung e.V. | Use of microbial hyaluronate lyase for softening connective tissue |
US9468671B2 (en) | 2002-05-04 | 2016-10-18 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
US8183350B2 (en) | 2002-05-04 | 2012-05-22 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
US9956273B2 (en) | 2002-05-04 | 2018-05-01 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
US8785606B2 (en) | 2002-05-04 | 2014-07-22 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
WO2004017044A3 (en) * | 2002-08-15 | 2004-09-10 | Acorda Therapeutics Inc | Chimeric protein |
US8679481B2 (en) | 2003-05-16 | 2014-03-25 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
US11141467B2 (en) | 2003-05-16 | 2021-10-12 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
US9528102B2 (en) | 2003-05-16 | 2016-12-27 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of CNS |
US8906363B2 (en) | 2003-05-16 | 2014-12-09 | Acorda Therapeutics, Inc. | Fusion proteins for the treatment of CNS |
US9839679B2 (en) | 2003-05-16 | 2017-12-12 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
EP2354155B1 (en) * | 2003-05-16 | 2017-05-03 | Acorda Therapeutics, Inc. | Fusion Proteins for Treatment of CNS |
US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
US8226941B2 (en) | 2004-05-18 | 2012-07-24 | Acorda Therapeutics, Inc. | Methods of purifying chondroitinase and stable formulations thereof |
US8236302B2 (en) | 2005-09-26 | 2012-08-07 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
US9834764B2 (en) | 2005-09-26 | 2017-12-05 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
US9402886B2 (en) | 2005-09-26 | 2016-08-02 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
US10323240B2 (en) | 2005-09-26 | 2019-06-18 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
US9410141B2 (en) | 2006-10-10 | 2016-08-09 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
US9102930B2 (en) | 2006-10-10 | 2015-08-11 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
US9987340B2 (en) | 2006-10-10 | 2018-06-05 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
US8404232B2 (en) | 2006-10-10 | 2013-03-26 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
Also Published As
Publication number | Publication date |
---|---|
AU1176595A (en) | 1995-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5916557A (en) | Methods of repairing connective tissues | |
Temenoff et al. | Tissue engineering for regeneration of articular cartilage | |
Angele et al. | Stem cell based tissue engineering for meniscus repair | |
Freed et al. | Joint resurfacing using allograft chondrocytes and synthetic biodegradable polymer scaffolds | |
Li et al. | Evaluation of articular cartilage repair using biodegradable nanofibrous scaffolds in a swine model: a pilot study | |
Ahmed et al. | Strategies for articular cartilage lesion repair and functional restoration | |
LeBaron et al. | Ex vivo synthesis of articular cartilage | |
Barrere et al. | Advanced biomaterials for skeletal tissue regeneration: Instructive and smart functions | |
EP1255577B1 (en) | Cellular matrix | |
O'DRISCOLL | Current concepts review-the healing and regeneration of articular cartilage | |
Freed et al. | Composition of cell‐polymer cartilage implants | |
US6451060B2 (en) | Cartilage matrix and in vitro production of transplantable cartilage tissue | |
EP3388091B1 (en) | Repair of cartilage tissue | |
JPH02209811A (en) | Composition for regenerating articular cartilage and bone,preparation of bone tissue transplant,and method for regenerating bone tissue | |
JP2001519700A (en) | New cartilage and how to use it | |
EP2302037A1 (en) | Method for non-autologous cartilage regeneration | |
WO1995013091A1 (en) | Methods of repairing connective tissues | |
Chicatun et al. | Collagen/chitosan composite scaffolds for bone and cartilage tissue engineering | |
Glowacki | In vitro engineering of cartilage | |
Galois et al. | Cartilage repair: Surgical techniques and tissue engineering using polysaccharide‐and collagen‐based biomaterials | |
JP6324395B2 (en) | Method of transplanting chondrocytes | |
Theodoridis et al. | In vivo cartilage regeneration with cell-seeded natural biomaterial scaffold implants: 15-year study | |
Vacanti et al. | Structural tissue engineering | |
Li et al. | Type I collagen-based template for meniscus regeneration | |
Awad et al. | Biomaterials for cartilage tissue engineering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |